RecruitingPhase 3

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Australia614 participantsStarted 2016-10-31

Plain-language summary

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases.
✓. Treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
✓. Treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.

What they're measuring

Overall survival

Timeframe: 7 years

Trial details

NCT IDNCT02821013

SponsorCanadian Cancer Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Janet Dancey

613-533-6430 jdancey@ctg.queensu.ca

View on ClinicalTrials.gov More Unresectable/Metastatic Melanoma trials